063160 — CKD Bio Income Statement
0.000.00%
Last trade - 00:00
- KR₩128bn
- KR₩271bn
- KR₩160bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | — | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 137,184 | 124,600 | 142,238 | 156,042 | 160,353 |
Cost of Revenue | |||||
Gross Profit | 36,174 | 27,864 | 13,306 | 16,790 | 8,013 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 121,825 | 117,246 | 153,967 | 170,882 | 180,505 |
Operating Profit | 15,359 | 7,354 | -11,728 | -14,839 | -20,153 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 15,638 | 7,059 | -13,358 | -18,590 | -24,197 |
Provision for Income Taxes | |||||
Net Income After Taxes | 12,265 | 6,207 | -6,577 | -16,703 | -24,193 |
Net Income Before Extraordinary Items | |||||
Net Income | 12,265 | 6,207 | -6,577 | -16,703 | -24,193 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 12,265 | 6,207 | -6,577 | -16,703 | -24,193 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2,291 | 1,188 | -1,169 | -3,043 | -4,431 |
Dividends per Share |